Clearside Biomedical IncNASDAQ:CLSD
- LAST PRICE1.3500
- TODAY'S CHANGE (%)-0.0100 (-0.7353%)
- Bid / Lots1.3300/ 1
- Ask / Lots1.4200/ 3
- Open / Previous Close1.3700 / 1.3600
- Day Range
- 52 Week Range
- Volume87,901
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLSD |
|---|---|---|
| 09:32 ET | 1220 | 1.37 |
| 09:36 ET | 1200 | 1.38 |
| 09:39 ET | 1500 | 1.3726 |
| 09:48 ET | 100 | 1.3711 |
| 09:52 ET | 100 | 1.36 |
| 10:06 ET | 367 | 1.3601 |
| 10:08 ET | 3858 | 1.4 |
| 10:33 ET | 100 | 1.38 |
| 10:35 ET | 100 | 1.39 |
| 10:44 ET | 100 | 1.39 |
| 10:48 ET | 200 | 1.38 |
| 11:00 ET | 100 | 1.38 |
| 11:02 ET | 7972 | 1.37 |
| 11:09 ET | 100 | 1.4 |
| 11:31 ET | 100 | 1.37 |
| 11:40 ET | 100 | 1.3725 |
| 11:45 ET | 100 | 1.37 |
| 11:49 ET | 250 | 1.389 |
| 11:51 ET | 100 | 1.39 |
| 12:02 ET | 4367 | 1.3899 |
| 12:12 ET | 2000 | 1.3701 |
| 12:14 ET | 268 | 1.385 |
| 12:16 ET | 800 | 1.4 |
| 12:32 ET | 300 | 1.37 |
| 12:43 ET | 100 | 1.4 |
| 12:50 ET | 579 | 1.37 |
| 12:52 ET | 200 | 1.385 |
| 12:56 ET | 1695 | 1.385 |
| 12:59 ET | 325 | 1.385 |
| 01:10 ET | 100 | 1.37 |
| 01:30 ET | 200 | 1.38 |
| 01:32 ET | 240 | 1.37 |
| 01:44 ET | 415 | 1.39 |
| 02:13 ET | 10083 | 1.36 |
| 02:20 ET | 700 | 1.36 |
| 02:24 ET | 9601 | 1.36 |
| 02:27 ET | 100 | 1.36 |
| 02:31 ET | 13588 | 1.3401 |
| 02:45 ET | 100 | 1.34 |
| 02:51 ET | 100 | 1.35 |
| 02:54 ET | 1037 | 1.36 |
| 02:56 ET | 1374 | 1.36 |
| 02:58 ET | 1860 | 1.36 |
| 03:00 ET | 478 | 1.36 |
| 03:03 ET | 464 | 1.35 |
| 03:21 ET | 8022 | 1.321 |
| 03:23 ET | 282 | 1.33 |
| 03:27 ET | 100 | 1.31 |
| 03:39 ET | 100 | 1.33 |
| 03:41 ET | 200 | 1.33 |
| 03:45 ET | 761 | 1.33 |
| 03:50 ET | 495 | 1.3303 |
| 03:52 ET | 100 | 1.33 |
| 03:54 ET | 150 | 1.3305 |
| 03:56 ET | 218 | 1.33 |
| 03:59 ET | 924 | 1.35 |
May 21, 2024
May 13, 2024
DJ Clearside Biomedical Is Maintained at Buy by HC Wainwright & Co., from 7:05AM ET on Monday May 13, 2024 by Dow Jones
7:05AM ET on Monday May 13, 2024 by Dow JonesDJ Clearside Biomedical Price Target Maintained With a $4.00/Share by Needham, from 5:44AM ET on Monday May 13, 2024 by Dow Jones
5:44AM ET on Monday May 13, 2024 by Dow Jones
May 9, 2024
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow Jones*DJ Clearside Biomedical 1Q Loss/Shr 17c >CLSD, from 4:05PM ET on Thursday May 09, 2024 by Dow Jones
4:05PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Clearside Biomedical Inc | 100.9M | -2.5x | --- |
Atara Biotherapeutics Inc | 75.1M | -0.3x | --- |
Coya Therapeutics Inc | 115.6M | -8.9x | --- |
Armata Pharmaceuticals Inc | 94.7M | -1.2x | --- |
Cue Biopharma Inc | 79.0M | -1.5x | --- |
LAVA Therapeutics NV | 69.4M | -2.5x | --- |
Company Information
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Contact Information
- Headquarters
- 900 North Point Parkway, Suite 200ALPHARETTA, GA, United States 30005
- Phone
- 678-270-3631
- Fax
- 678-270-4033
Executives
- Independent Chairman of the Board
- William Humphries
- President, Chief Executive Officer, Director
- George Lasezkay
- Chief Financial Officer
- Charles Deignan
- Chief Medical Officer
- Victor Chong
- Director
- Anthony Gibney
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $100.9M |
|---|---|
Revenue (TTM) | $8.5M |
Shares Outstanding | 74.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.35 |
EPS | $-0.54 |
Book Value | $-0.25 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 11.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -282.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
